Skip to main content
. Author manuscript; available in PMC: 2025 Dec 24.
Published in final edited form as: Sleep Med. 2025 Oct 14;136:106853. doi: 10.1016/j.sleep.2025.106853

Fig. 1.

Fig. 1.

Change in AHI, pAHI, and body weight. Change from baseline in AHI (number of apneas and hypopneas events per hour of sleep) and percent change from baseline in body weight. Study 1 also includes pAHI measurements carried out with WatchPAT 300. Data points from baseline to Week 52 for Study 1 and Study 2 are shown according to the weeks since randomization, derived from a mixed-model-for-repeated-measures analysis for the efficacy estimand. Data points are LSMean ± SE. ***p < 0.001 versus placebo. AHI = apnea-hypopnea index; LSMean = least-squares mean; PBO = placebo; SE = standard error; TZP = tirzepatide maximum tolerated dose (MTD, 10 mg or 15 mg once weekly).